[{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"DNA.HTI","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aelix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aelix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1.HTI","moa":"HIV T-cell immunogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vesatolimod","moa":"Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ChAdOx1.HTI","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Aelix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aelix Therapeutics \/ Aelix Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aelix Therapeutics \/ Aelix Therapeutics"}]